Nobivac Bb (--) - Lyophilisate and solvent for nasal suspension
Nobivac Bb (--) - Lyophilisate and solvent for nasal suspension
Authorised
- Bordetella bronchiseptica, strain B-C2, Live
Product identification
Medicine name:
Nobivac Bb (--) - Lyophilisate and solvent for nasal suspension
Active substance:
- Bordetella bronchiseptica, strain B-C2, Live
Target species:
-
Cat
Route of administration:
-
Nasal use
Product details
Active substance and strength:
-
Bordetella bronchiseptica, strain B-C2, LivePresentation_strength:10⁶·³–10⁸·³ CFU Reference:Hse Comments:Live Index:0
Pharmaceutical form:
-
Lyophilisate and solvent for suspension for nasal administration
Anatomical therapeutic chemical veterinary (ATCvet) codes:
- QI06AE02
Legal status of supply:
-
Veterinary medicinal product subject to veterinary prescription
Authorisation status:
-
Valid
Authorised in:
-
Austria
-
Belgium
-
Bulgaria
-
Croatia
-
Cyprus
-
Czechia
-
Denmark
-
Estonia
-
Finland
-
France
-
Germany
-
Greece
-
Hungary
-
Iceland
-
Ireland
-
Italy
-
Latvia
-
Liechtenstein
-
Lithuania
-
Luxembourg
-
Malta
-
Netherlands
-
Norway
-
Poland
-
Portugal
-
Romania
-
Slovakia
-
Slovenia
-
Spain
-
Sweden
-
United Kingdom (Northern Ireland)
Available in:
-
Belgium
-
Netherlands
Package description:
- Packaging:Vial (glass) in plastic box, Package_size:Lyophilisate: 5 vials; Solvent: 5 vials, Content:Lyophilisate: 1 dose; solvent: 0.5 ml
- Packaging:Vial (glass) in cardboard box, Package_size:Lyophilisate: 5 vials; Solvent: 5 vials, Content:Lyophilisate: 1 dose; solvent: 0.5 ml
Additional information
Entitlement type:
-
Marketing Authorisation
Legal basis of product authorisation:
-
Complete application (stand-alone) - Council Directive 81/851/EEC
Marketing authorisation holder:
- Intervet International B.V.
Marketing authorisation date:
Manufacturing sites for batch release:
- Intervet International B.V.
Responsible authority:
- European Commission
Authorisation number:
This information is not available for this product.
Date of authorisation status change:
To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet
Documents
Combined File of all Documents
English (PDF)
Download Published on: 16/11/2022
Bulgarian (PDF)
Published on: 16/11/2022
Croatian (PDF)
Published on: 16/11/2022
Czech (PDF)
Published on: 16/11/2022
Danish (PDF)
Published on: 16/11/2022
Dutch (PDF)
Published on: 16/11/2022
Estonian (PDF)
Published on: 16/11/2022
Finnish (PDF)
Published on: 16/11/2022
French (PDF)
Published on: 16/11/2022
German (PDF)
Published on: 16/11/2022
Greek (PDF)
Published on: 16/11/2022
Hungarian (PDF)
Published on: 16/11/2022
Icelandic (PDF)
Published on: 16/11/2022
Italian (PDF)
Published on: 16/11/2022
Latvian (PDF)
Published on: 16/11/2022
Lithuanian (PDF)
Published on: 16/11/2022
Maltese (PDF)
Published on: 16/11/2022
Norwegian (PDF)
Published on: 16/11/2022
Polish (PDF)
Published on: 16/11/2022
Portuguese (PDF)
Published on: 16/11/2022
Romanian (PDF)
Published on: 16/11/2022
Slovak (PDF)
Published on: 16/11/2022
Slovenian (PDF)
Published on: 16/11/2022
Spanish (PDF)
Published on: 16/11/2022
Swedish (PDF)
Published on: 16/11/2022
ema-puar-nobivac-bb-epar-scientific-discussion-en.pdf
English (PDF)
Download Published on: 15/03/2023
